Celularity Inc
CELUNasdaq
$0.78
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↓ -63.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$20.0M
Enterprise Value
$47.6M
P/E
—
P/S
0.8
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$26.6M
Net Income (TTM)
-$91.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-230.9%
Net Margin
-345.4%
ROE
241.0%
ROIC
—
Debt / Equity
-0.9
Net Cash
-$27.6M
Return 1Y
-64.5%
Company profile
Celularity Inc. develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
- CEO
- Robert Joseph Hariri Gordon
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 220
- Headquarters
- New Jersey
- Website
- celularity.com
Management & directors
- Brigido StephenPres., Functional Regeneration
- Haines John RSenior Exec Vice President
- Hariri Robert JChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
CELU Q4 2025 Earnings
Period ends 2025-12-31
MetricActualYoY
Revenue$4.1M↓ -77.4%
Diluted EPS-$0.85↑ +46.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $14.3M | $21.3M | $18.0M | $22.8M | $54.2M | $26.6M |
| Gross profit | $9.3M | $11.7M | -$1.7M | $6.8M | — | — |
| Operating income | -$151.9M | -$109.1M | -$25.6M | -$192.3M | -$38.4M | -$61.3M |
| Net income | -$208.2M | -$100.1M | $14.2M | -$196.3M | -$57.9M | -$91.7M |
| Diluted EPS | — | -$1.49 | $0.95 | -$11.02 | -$2.64 | -$3.59 |
| Operating cash flow | -$63.2M | -$110.1M | -$137.9M | -$38.7M | -$6.4M | -$13.3M |
| Free cash flow | -$91.0M | -$116.3M | -$143.1M | -$39.7M | -$6.6M | — |
| Gross margin | 65.5% | 54.8% | -9.4% | 29.7% | — | — |
| Operating margin | -1064.0% | -511.2% | -142.4% | -844.4% | -70.7% | -230.9% |
| Net margin | -1458.4% | -469.3% | 79.0% | -862.0% | -106.8% | -345.4% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.7M | $12.1M | $9.3M | $18.1M | $11.4M | $5.7M | $5.3M | $4.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.4M | -$10.2M | -$11.5M | -$9.3M | -$10.5M | -$15.9M | -$12.9M | -$22.1M |
| Net income | -$22.0M | -$6.5M | -$16.1M | -$13.3M | -$19.8M | -$24.5M | -$23.1M | -$24.4M |
| Diluted EPS | -$1.03 | -$0.30 | -$0.73 | -$0.58 | -$0.84 | -$1.02 | -$0.88 | -$0.85 |
| Operating cash flow | -$4.4M | -$3.4M | -$144,000.00 | $1.6M | -$3.0M | -$999,000.00 | -$4.2M | -$5.1M |
| Free cash flow | -$4.4M | -$3.5M | -$144,000.00 | $1.5M | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -50.2% | -84.0% | -124.0% | -51.2% | -91.8% | -276.6% | -244.1% | -537.5% |
| Net margin | -149.9% | -53.6% | -173.2% | -73.3% | -172.9% | -427.5% | -436.7% | -593.6% |
Company news
Jun 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-13 | Hariri Robert J· Chief Executive Officer | Tax withholding | 1,182 | $1.28 | $1,512.96 | filing |
| 2026-04-13 | Haines John R· Senior Exec Vice President | Tax withholding | 583 | $1.28 | $746.24 | filing |
| 2026-04-13 | Brigido Stephen· Pres., Functional Regeneration | Tax withholding | 268 | $1.28 | $343.04 | filing |
| 2026-04-13 | Hariri Robert J· Chief Executive Officer | Option exercise | 3,281 | $0.00 | $0.00 | filing |
| 2026-04-13 | Brigido Stephen· Pres., Functional Regeneration | Option exercise | 821 | $0.00 | $0.00 | filing |
| 2026-04-13 | Haines John R· Senior Exec Vice President | Option exercise | 1,641 | $0.00 | $0.00 | filing |
| 2026-01-12 | LeVien Vincent | Award | 28,847 | $0.00 | $0.00 | filing |
| 2026-01-12 | Parks Diane L. | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-01-12 | Diamandis Peter | Award | 20,385 | $0.00 | $0.00 | filing |
| 2026-01-12 | Parks Diane L. | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-01-12 | Diamandis Peter | Award | 20,385 | $0.00 | $0.00 | filing |
| 2026-01-12 | LeVien Vincent | Award | 28,847 | $0.00 | $0.00 | filing |
| 2026-01-12 | Ling Geoffrey M.D. | Award | 19,231 | $0.00 | $0.00 | filing |
| 2026-01-12 | Ling Geoffrey M.D. | Award | 19,231 | $0.00 | $0.00 | filing |
| 2025-12-29 | LeVien Vincent | Award | 125,000 | $0.00 | $0.00 | filing |
| 2025-12-29 | Ling Geoffrey M.D. | Award | 125,000 | $0.00 | $0.00 | filing |
| 2025-12-29 | Parks Diane L. | Award | 125,000 | $0.00 | $0.00 | filing |
| 2025-12-29 | Diamandis Peter | Award | 125,000 | $0.00 | $0.00 | filing |
| 2025-12-19 | Parks Diane L. | Award | 67,416 | $0.00 | $0.00 | filing |
| 2025-12-19 | Ling Geoffrey M.D. | Award | 67,416 | $0.00 | $0.00 | filing |
| 2025-12-19 | Diamandis Peter | Award | 67,416 | $0.00 | $0.00 | filing |
| 2025-11-19 | Parks Diane L. | Award | 61,539 | $0.00 | $0.00 | filing |
| 2025-11-19 | LeVien Vincent | Award | 3,699 | $0.00 | $0.00 | filing |
| 2025-11-19 | Ling Geoffrey M.D. | Award | 44,379 | $0.00 | $0.00 | filing |
| 2025-11-19 | Diamandis Peter | Award | 47,042 | $0.00 | $0.00 | filing |
Latest 25 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.